Table 1.
Abbreviated* melanoma brain metastasis patient data.
| Variable | Level | N (%) = 17 |
|---|---|---|
| Patient Characteristics | ||
| Age (years) | Median (range) | 54 (34–81) |
| Gender | Male | 13 (76.5%) |
| Female | 4 (23.5%) | |
| Race | White | 17 |
| Brain Metastases at Melanoma | Yes | 6 (35.3%) |
| Diagnosis | No | 11 (64.7%) |
| Active systemic disease | Yes | 14 (82.4%) |
| No | 3 (17.6%) | |
| Presence of extra-cranial disease | Yes | 14 (82.4%) |
| No | 3 (17.6%) | |
| Number of Brain Metastases | Median (range) | 2 (1–6) |
| Pre-treatment LDH | Median (range) | 202 (121–312) |
| BRAF mutation status | Mutated | 9 (52.9%) |
| Wild-type | 8 (47.1%) | |
| Melanoma molGPA | 1–1.5 | 3 (17.6%) |
| 2.0–2.5 | 9 (52.9%) | |
| 3.0–3.5 | 4 (23.5%) | |
| 4.0 | 1 (5.9%) | |
| Treatment Characteristics | ||
| BRAF Inhibitor Use | Yes | 5 (29.4%) |
| No | 12 (70.6%) | |
| Immunotherapy Timing | After RT | 11 (64.7%) |
| Before and After RT | 6 (35.3%) | |
| Type of RT | SRS | 15 (88.2%) |
| WBRT | 2 (11.8%) |
*
See Source file for detailed version of Table 1 patient date.